Abstract: Antimicrobial compounds of the formulae: ##STR1## wherein R and R.sub.1 =H, lower alkyl, halogen, methoxy, hydroxy, nitro, carboxy, aryl (preferably phenyl) substituted aryl (preferably substituted by lower alkyl) and sulfamyl, and R.sub.2 =hydrogen, lower alkyl, aryl (preferably phenyl) and substituted aryl (preferably substituted by lower alkyl) and wherein n is an integer from 2-20, are provided. Also provided are the method of producing such compounds.

Abstract: The invention relates to the production of compounds of the general formula: ##STR1## wherein X is selected from the group consisting of oxygen, CH.sub.2 and CH radicals, and when X designates oxygen, R designates alkyl, isoalkyl, aralkyl, and substituted aralkyl groups and when X designates CH.sub.2 then R designates alkyl, phenyl or substituted phenyl group, and A-B is a single bond, and when X designates CH.sub.2, R designates alkyl, phenyl or substituted phenyl groups and A-B is a double bond; and physiologically acceptable salts of these, and pharmaceutical compositions containing the same as active ingredient.

Abstract: Iodophor powders are prepared by suspending a particulate iodophor-forming polymer in an iodine solution in which the polymer is insoluble, and adding to the suspension a solution of an iodide in a solvent system miscible with the solvent of the iodine solution, to cause the formation of an iodophor. The iodophor can be separated from the solvent by filtration.

Abstract: Compounds of the general formula: ##STR1## wherein X is selected from the group consisting of oxygen, CH.sub.2 and CH radicals, and when X designates oxygen, R designates alkyl, isoalkyl, aralkyl, and substituted aralkyl groups and when X designates CH.sub.2 then R designates alkyl, phenyl or substituted phenyl group, and A-B is a single bond, and when X designates CH.sub.2 R designates alkyl, phenyl or substituted phenyl groups and A-B is a double bond; and physiologically acceptable salts of these, and mydriatic pharmaceutical compositions containing the same as active ingredient.

Abstract: A kit for aseptic changing of a dressing such as a catheter dressing includes a disposable tray made of a light plastic sheet material and having a cover sheet adhering thereto and closing depressions in the tray. This cover sheet is removable from the tray so as to render the depressions thereof accessible. In these depressions there are a number of items including packettes of antiseptic germicide solution and ointment, cleansing swabs, and the like, as well as a number of swabsticks, gauze pads, and adherent tape. These items also may include a sheet of drape material, a plastic bag for receiving a previously applied dressing which is removed, and plastic gloves. One of the items included in the tray is a suitable cutting tool, such as a disposable scissors.

Abstract: A syringe, particularly a vaginal douche, has a cannula consisting of an elongated hollow tubular body having one open end and an opposed transverse end wall formed with an opening through which a central axis of the cannula body extends. The cannula body has substantially midway between its ends a transverse minimum cross section while tapering only slightly from the transverse end wall toward the minimum cross section. Between its open end and its minimum cross section the cannula body tapers to a substantially greater degree and has the configuration of part of a hollow cone. At its exterior between its minimum cross section and transverse end wall the cannula body is formed with grooves uniformly distributed about the central axis of the cannula body and separated from each other by ribs. Adjacent but inwardly of these ribs the cannula body is formed with additional openings passing therethrough so that a liquid can discharge through the cannula openings.

Abstract: A device which is adapted to receive a liquid having particles suspended therein includes a one-piece plastic container having an open top, a closed bottom, and an endless side wall extending between the open top and closed bottom to define with the bottom of the container a hollow interior thereof. A partition structure which is integral with the side wall of the container is situated between the open top and closed bottom thereof to define in the interior of the container upper and lower chambers separated from each other by the partition structure. This partition structure extends across the interior of the container and has therein a free edge defining with an inner surface of the side wall of the container an opening through which the above chambers communicate with each other.

Abstract: An improved process for preparing iodophor preparations which comprises adding an ion selected from the group consisting of iodate, bromate, chlorite, chromate, hypochlorite, permanganate and persulfate ions and hydrogen peroxide to the iodine carrier selected from the group consisting of povidone, cationic, anionic and nonionic detergent compounds and an iodide salt, to result in a substantially pure iodophor compound which is virtually free of autodegraded iodide ion contamination and unreacted elemental iodine, said iodophor compounds exhibiting an enhanced stability. The process is also applicable to eliminate the presence of elemental iodine contaminants, iodide contamination and loss of titratable iodine during the process preparing pharmaceutical dosage forms containing iodophor active ingredients to enhance the stability and potency of the respective product.

Abstract: Novel spiro (1,3-dioxolane-4,3') quinuclidine compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2, which may be identical or different, each designates a member of the group hydrogen, alkyl or aryl; a process for the production of these and pharmaceutical compositions of matter containing such compound as active ingredient.

Abstract: Compounds of the general formula ##STR1## wherein X is selected from the group consisting of oxygen CH.sub.2 and CH radicals, and when X designates oxygen, R designates alkyl, isoalkyl, aralkyl, and substituted aryl groups and when X designates ##STR2## then R designates alkyl, phenyl or substituted phenyl group, and A--B is a single bond and when X designates >CH, and A--B is a double bond, R designates alkyl, phenyl or substituted phenyl groups and physiologically acceptable salts of these, and pharmaceutical compositions containing same as active ingredient.

Abstract: Choline salicylate is stabilized in solid form by means of a metal salicylate having a valence of at least 2, preferably aluminum, bismuth, calcium or magnesium salicylate. The composition is stabilized to a still greater degree by the addition thereto of carboxy-methyl cellulose. A still greater degree of stabilization is achieved by forming a complex of the choline salicylate, metal salicylate and carboxy-methyl cellulose. The complex is formed by preparing a solution of the carboxy-methyl cellulose, choline salicylate and metal salicylate, permitting complexng reaction to take place and drying. All of these stabilized forms of choline salicylate are used in solid dosage forms such as granules, tablets, capsules and supporitories for administration to animals and humans, in the course of choline salicylate therapy, to elevate the blood levels of salicylate ion.

Abstract: Choline salicylate-silanized silicon dioxide a stable solid, non-hygroscopic composition possessing the full spectrum of analgesic, anti-pyretic and anti-inflammatory properties of choline salicylate is prepared by reaching a choline ion with a salicylate ion and then combining with silanized silicon dioxide in the presence of an inert anhydrous solvent to form the new composition. Solid pharmaceutical dosage forms are prepared with the new composition which are useful in the treatment of musculo-skeletal disease, the relief of pain and the lowering of fever in humans and animals. A method for increasing the concentration of blood salicylate ion through the oral administration of the aforesaid choline salicylate-silanized silicon dioxide and pharmaceutical composition containing the same, is presented.

Abstract: Choline salicylate sulfite and choline salicylate alkali metal sulfite-containing compounds of the formula, ##SPC1##Wherein Me represents the sodium, potassium or lithium ion and R represents the sulfite, bisulfite, metabisulfite, dithionate, hydrosulfite and hyposulfite groups are described. Said compounds are stable and inhibit the formation of color in pharmaceutical preparations containing the same. The method for the preparation of choline salicylate sulfite and choline salicylate alkali metal sulfite-containing compounds, and pharmaceutical dosage forms containing the same are disclosed together with a method for their use to inhibit color formation.